SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read More
Tag: Calquence
NICE backs AstraZeneca’s Calquence for CLL
Recommendation offers new chemotherapy-free treatment options for these patients
Read More
Calquence tops Imbruvica in chronic lymphocytic leukaemia study
BTK inhibitor demonstrated non-inferior progression-free survival compared to Imbruvica
Read More
NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The recommendations are positive for a select population of patients with CLL
Read More
Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read More
EU OK for AZ’s Calquence in CLL
BTK inhibitor approved based on results from two phase III trials
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
AZ’ Calquence shows promise for COVID-19
Improved markers of inflammation and reduced oxygen requirements were seen in most patients
Read More
AZ to test Calquence for COVID-19
The moves follows ‘strong scientific evidence’ indicating the role of the BTK pathway in the production of inflammatory cytokines
Read More
AZ’ Calquence boosts PFS in CLL patients
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Read More
AZ’ Calquence granted US Breakthrough Therapy Designation
The drug has been approved for chronic lymphocytic leukaemia.
Read More
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
